Kynurenine Pathway Dysregulation in 4R-Tauopathies

Kynurenine Pathway Dysregulation in 4R-Tauopathies

Overview

The [kynurenine pathway (KP)](/mechanisms/kynurenine-pathway) is the major catabolic route for the essential amino acid tryptophan, accounting for approximately 95% of its degradation in the body. This metabolic cascade generates neuroactive intermediates that profoundly influence the central nervous system through modulation of glutamate neurotransmission, oxidative stress, neuroinflammation, and immune signaling. Dysregulation of the kynurenine pathway has been increasingly implicated in the pathogenesis of neurodegenerative tauopathies, with particular relevance to the four-repeat (4R) tauopathies — [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy), [Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration), [Argyrophilic Grain Disease (AGD)](/diseases/argyrophilic-grain-disease), [Globular Glial Tauopathy (GGT)](/diseases/globular-glial-tauopathy), and [Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)](/diseases/ftdp-17) [@kynurenine2025][@therapeutic2023].

Kynurenine Pathway Dysregulation in 4R-Tauopathies

Overview

The [kynurenine pathway (KP)](/mechanisms/kynurenine-pathway) is the major catabolic route for the essential amino acid tryptophan, accounting for approximately 95% of its degradation in the body. This metabolic cascade generates neuroactive intermediates that profoundly influence the central nervous system through modulation of glutamate neurotransmission, oxidative stress, neuroinflammation, and immune signaling. Dysregulation of the kynurenine pathway has been increasingly implicated in the pathogenesis of neurodegenerative tauopathies, with particular relevance to the four-repeat (4R) tauopathies — [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy), [Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration), [Argyrophilic Grain Disease (AGD)](/diseases/argyrophilic-grain-disease), [Globular Glial Tauopathy (GGT)](/diseases/globular-glial-tauopathy), and [Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)](/diseases/ftdp-17) [@kynurenine2025][@therapeutic2023].

All five diseases are classified as 4R-tauopathies, meaning they involve the preferential accumulation of tau isoforms containing four microtubule-binding repeats, encoded by [MAPT](/genes/mapt) exon 10. Despite this shared molecular signature, they differ markedly in clinical phenotype, regional vulnerability, and cellular distribution of tau pathology. The kynurenine pathway provides a mechanistic link between these distinct patterns of neurodegeneration through its cell-type-specific metabolites and effects on glutamate signaling, oxidative stress, and neuroinflammation.

Pathway Overview

The KP branches into two opposing metabolic directions:

• Neuroprotective branch (astrocytes): [Kynurenine aminotransferases (KATs I–IV)](/entities/kynurenine-aminotransferase) convert kynurenine to [kynurenic acid (KYNA)](/mechanisms/kynurenine-pathway), which antagonizes [NMDA receptors](/entities/nmda-receptor) and provides antioxidant effects.
• Neurotoxic branch (microglia): [Kynurenine 3-monooxygenase (KMO)](/entities/kynurenine-3-monooxygenase) converts kynurenine to [3-hydroxykynurenine (3-HK)](/mechanisms/kynurenine-pathway), which generates reactive oxygen species (ROS) and is further metabolized to [quinolinic acid (QUIN)](/mechanisms/kynurenine-pathway), a selective [NMDA receptor](/entities/nmda-receptor) agonist that promotes excitotoxicity and tau hyperphosphorylation.

4R-Tauopathy Overview

All five diseases in this group share the molecular feature of 4R tau predominance, but differ substantially in cellular tropism and clinical presentation:

| Disease | Key Pathology | Primary Cell Types Affected | Hallmark Glial Lesion | Key Brain Regions |
|---------|--------------|----------------------------|-----------------------|-------------------|
| [PSP](/diseases/progressive-supranuclear-palsy) | NFT, tufted astrocytes | Subcortical nuclei, brainstem | Tufted astrocytes | Subthalamic nucleus, substantia nigra, PPN, brainstem |
| [CBD](/diseases/corticobasal-degeneration) | Ballooned neurons, astrocytic plaques | Cortex, basal ganglia | Astrocytic plaques | Motor cortex, premotor, parietal |
| [AGD](/diseases/argyrophilic-grain-disease) | Argyrophilic grains, coiled bodies | Limbic system | Coiled bodies (oligodendrocytes) | Amygdala, entorhinal cortex, hippocampus |
| [GGT](/diseases/globular-glial-tauopathy) | Globular inclusions | Frontotemporal/motor | GOIs, GAIs (globular glial) | White matter, motor cortex, corticospinal tracts |
| [FTDP-17](/diseases/ftdp-17) | NFT, variable glial | Frontotemporal cortex | Variable | Frontal, temporal cortex, substantia nigra |

Data synthesized from [@4rcomparison2024] and cross-referenced with individual disease pages.

Disease-Specific Kynurenine Pathway Dysregulation

Progressive Supranuclear Palsy (PSP)

PSP is characterized by prominent brainstem and subcortical neurodegeneration, with tufted astrocytes as the hallmark glial lesion. The kynurenine pathway is dysregulated in PSP through several interconnected mechanisms:

IDO/TDO Activation: Indoleamine 2,3-dioxygenase (IDO1) is induced in activated [microglia](/cell-types/microglia) within affected brainstem nuclei — particularly the [subthalamic nucleus](cell-types/subthalamic-nucleus), [substantia nigra](/brain-regions/substantia-nigra), and pontine nuclei — by pro-inflammatory cytokines including IFN-gamma and TNF-alpha. This activation shunts tryptophan toward kynurenine production, depleting tryptophan availability locally. TDO2 is also upregulated in the brainstem in PSP, contributing to sustained kynurenine production [@kynurenine2022].

QUIN Accumulation in Brainstem: The selective loss of [GABAergic neurons](/cell-types/gabaergic-neurons) in the [subthalamic nucleus](cell-types/subthalamic-nucleus) and substantia nigra pars reticulata of PSP brains creates an excitotoxic vulnerability. QUIN, produced locally by activated microglia, acts as a selective agonist of [NMDA receptors](/entities/nmda-receptor) containing GluN2A/GluN2B subunits — the same receptor subtypes highly expressed on brainstem GABAergic neurons. Elevated QUIN in the midbrain and pons contributes to the characteristic supranuclear gaze palsy and axial rigidity through excitotoxic targeting of oculomotor and postural control circuits [@chen2022].

Shift Toward Neurotoxic Branch: PSP brainstem tissue shows decreased [KYNA](/mechanisms/kynurenine-pathway) levels relative to age-matched controls, reflecting reduced astrocytic KAT activity in affected nuclei. Tufted astrocytes — the defining glial lesion of PSP — express lower levels of KATs compared to normal astrocytes, reducing the neuroprotective capacity of the KP in regions with highest tau burden. This creates a feed-forward loop: tau pathology activates microglia, which produce QUIN and 3-HK, which further damages the neurons that are already vulnerable to tau-induced dysfunction [@gidoni2024].

Link to Neuroinflammation: The [pedunculopontine nucleus (PPN)](/brain-regions/pedunculopontine-nucleus) and other brainstem cholinergic nuclei show prominent microglial activation in PSP. IDO1 induction in these nuclei converts tryptophan to kynurenine, driving the neurotoxic branch of the KP. The resulting kynurenine/tryptophan ratio elevation correlates with disease severity and CSF neurofilament light chain levels, suggesting kynurenine pathway metabolites may serve as biomarkers of neuroinflammatory burden in PSP [@baresa2023].

Corticobasal Degeneration (CBD)

CBD exhibits cortical and subcortical involvement with pronounced asymmetry and early basal forebrain cholinergic involvement. The kynurenine pathway contributes to the characteristic cortical dysfunction through distinct mechanisms:

Cortical Microglial Activation and IDO1: The marked asymmetric cortical involvement in CBD — affecting motor, premotor, and parietal cortices — is associated with dense microglial activation in affected regions. IDO1 expression is elevated in activated [microglia](/cell-types/microglia) in CBD cortical tissue, particularly in layers III and V where pyramidal neurons show tau pathology and degeneration. This IDO1 activation drives local tryptophan depletion and kynurenine overproduction in precisely the cortical regions most affected by tau pathology [@kynurenine2022].

Excitotoxicity Targeting Cortical GABAergic Interneurons: CBD shows early and severe involvement of [parvalbumin-positive GABAergic interneurons](/cell-types/gabaergic-interneurons) in the cortex. These interneurons express high levels of [NMDA receptors](/entities/nmda-receptor) and are exquisitely sensitive to QUIN-mediated excitotoxicity. Elevated cortical QUIN in CBD contributes to the cortical inhibition deficits that underlie the characteristic apraxia and alien limb phenomena. The microglial production of QUIN in CBD cortex preferentially targets these vulnerable GABAergic populations, amplifying the cortical dysfunction beyond what tau pathology alone would produce [@chen2022].

KYNA Deficiency in Cortex: Astrocytic plaques — the hallmark astroglial lesion of CBD — are dysfunctional compared to normal astrocytes. CBD astrocytes show reduced KAT expression and lower KYNA production capacity in affected cortical regions. The ring-like tau-positive distal processes of astrocytic plaques likely impair the astrocytic function of glutamate uptake and KYNA synthesis, creating a neurotoxic environment with elevated extracellular glutamate and reduced KYNA-mediated neuroprotection [@role2022].

Basal Forebrain Cholinergic Vulnerability: The early degeneration of [basal forebrain cholinergic neurons](/brain-regions/basal-forebrain) in CBD contributes to cognitive decline and cortical atrophy. These neurons are particularly sensitive to excitotoxicity. Elevated kynurenine pathway activity in the basal forebrain — driven by microglial activation in this region — generates QUIN that targets these cholinergic neurons, accelerating their degeneration and contributing to the cognitive phenotype of CBD [@dynamic2022].

Argyrophilic Grain Disease (AGD)

AGD is characterized by argyrophilic grains in neuronal dendrites with prominent limbic system involvement. The kynurenine pathway dysregulation in AGD is particularly relevant to the limbic predilection:

Limbic IDO Activation: The amygdala, [hippocampus](/brain-regions/hippocampus), and [entorhinal cortex](/brain-regions/entorhinal-cortex) — the earliest and most severely affected regions in AGD — show prominent microglial activation with elevated IDO1 expression. The limbic predilection of AGD may be partly explained by the high density of microglia in these regions and their heightened activation response to tau pathology. IDO activation in the amygdala contributes to the neuropsychiatric features (anxiety, depression, emotional lability) that are prominent in AGD [@baresa2023].

Entorhinal Cortex Kynurenine Overproduction: The entorhinal cortex, particularly Layer II stellate neurons, is the earliest site of pathology in AGD (Stage I). These neurons are surrounded by activated microglia producing kynurenine pathway metabolites. The entorhinal cortex has a relatively high density of NMDA receptors and is critical for hippocampal-entorhinal connectivity. QUIN-mediated excitotoxicity of entorhinal neurons contributes to the memory impairment characteristic of AGD, particularly the early episodic memory deficits that often precede other symptoms [@kynurenine2022].

Coiled Bodies and Oligodendroglial KP: AGD features prominent [coiled bodies](/cell-types/oligodendrocytes) — oligodendroglial inclusions composed of hyperphosphorylated 4R tau. These occur predominantly in white matter tracts, particularly in limbic white matter. Oligodendrocytes in AGD show increased KMO expression relative to controls, shifting the local KP toward 3-HK and QUIN production. This contributes to white matter dysfunction and myelin loss, which may explain the connectivity disruption visible on diffusion tensor imaging in AGD patients [@kmo2008].

Kynurenine-Tau Crosstalk in Grains: Argyrophilic grains are pre-tangle lesions composed of hyperphosphorylated 4R tau in neuronal dendrites. QUIN can directly promote tau hyperphosphorylation through activation of CDK5 and GSK3-beta kinases. The bidirectional relationship between kynurenine pathway dysregulation and tau pathology is particularly evident in AGD, where the argyrophilic grains represent an early stage of tau aggregation that may be accelerated by local QUIN production [@gidoni2024].

Globular Glial Tauopathy (GGT)

GGT is defined by distinctive globular inclusions in glial cells (GOIs in oligodendrocytes, GAIs in astrocytes), with variable white matter involvement depending on subtype. The kynurenine pathway contributes to the severe white matter pathology characteristic of GGT:

White Matter Oligodendrocyte KMO Upregulation: GGT Type I (frontotemporal) and Type II (motor-predominant) both show severe white matter involvement with GOI burden correlating with myelin loss and axonal damage. Oligodendrocytes — the myelin-producing cells of the CNS — show elevated KMO expression in GGT white matter. This shifts the KP toward the neurotoxic branch locally, producing 3-HK and QUIN within the white matter itself. The resulting oxidative stress damages both oligodendrocytes and myelinated axons, creating a self-amplifying cycle of white matter degeneration [@kmo2008].

Myelin Vulnerability to QUIN/3-HK: Oligodendrocytes are particularly vulnerable to oxidative stress and excitotoxicity compared to neurons. The 3-HK and QUIN produced locally by KMO-expressing oligodendrocytes in GGT white matter directly damage myelin-producing cells, contributing to the severe demyelination observed in GGT. This is distinct from other 4R-tauopathies where white matter involvement is more moderate. The severe white matter pathology in GGT is a key distinguishing feature that may be partly attributable to local kynurenine pathway dysregulation [@dynamic2022].

Astrocytic KAT Deficiency in GGT: GAIs (globular astroglial inclusions) in GGT astrocytes are associated with reduced KAT expression in affected cells. This mirrors the astrocytic dysfunction seen in CBD, but the globular morphology of the inclusions suggests a different pattern of astrocyte stress response. The reduced KYNA production by GGT astrocytes fails to protect the surrounding neuropil from excitotoxicity, compounding the damage from oligodendrocyte-derived QUIN and 3-HK [@role2022].

Type-Specific KP Patterns: GGT Type II (motor-predominant) shows the highest burden of white matter pathology and the most severe oligodendroglial GOI burden. This correlates with elevated KMO expression in motor-related white matter tracts (corticospinal tracts, corpus callosum). The resulting QUIN and 3-HK production in motor white matter contributes to the upper and lower motor neuron signs that characterize Type II. Type III (combined pattern) shows intermediate KP dysregulation across both frontotemporal white matter and motor tracts [@4rcomparison2024].

Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)

FTDP-17 is caused by [MAPT](/genes/mapt) mutations and shows variable phenotypes depending on the specific mutation. Kynurenine pathway dysregulation in FTDP-17 represents a secondary consequence of mutant tau-induced cellular stress:

MAPT Mutation-Driven Microglial Activation: Pathogenic [MAPT](/genes/mapt) mutations — particularly P301L, P301S, and splicing mutations affecting exon 10 — induce robust microglial activation in affected brain regions. Mutant tau aggregates trigger the NLRP3 inflammasome in microglia, leading to IDO1 induction and pro-inflammatory cytokine production (IL-1beta, TNF-alpha). The resulting IDO activation shunts tryptophan toward kynurenine, creating a neurotoxic microenvironment in frontotemporal cortex and basal ganglia [@baresa2023].

Excitotoxicity in Frontotemporal Cortex: The frontotemporal cortical neurodegeneration in FTDP-17 is amplified by QUIN-mediated excitotoxicity. Frontotemporal pyramidal neurons express NMDA receptors and are vulnerable to the elevated QUIN produced by activated microglia. In splicing mutations (e.g., S305I, +3 intronic), the disproportionate accumulation of 4R tau in Layer V pyramidal neurons coincides with locally elevated kynurenine pathway activity, accelerating the death of these projection neurons [@kynurenine2022].

Tau-Kynurenine Feed-Forward Loop: Mutant tau and kynurenine pathway metabolites create a feed-forward pathological loop in FTDP-17. QUIN activates kinase pathways (CDK5, GSK3-beta) that hyperphosphorylate both wild-type and mutant tau, promoting its aggregation. This increased tau aggregation further activates microglia, driving more IDO expression and kynurenine production. This positive feedback loop may explain the relatively rapid progression of FTDP-17 compared to sporadic 4R-tauopathies [@gidoni2024].

Substantia Nigra Kynurenine Dysregulation: FTDP-17 cases with significant parkinsonian features (particularly P301L and V337M mutations) show substantial [substantia nigra](/brain-regions/substantia-nigra) degeneration. The kynurenine pathway is locally dysregulated in the substantia nigra, with elevated IDO and KMO activity producing high local concentrations of QUIN and 3-HK. These metabolites target the dopaminergic neurons of the substantia nigra pars compacta, contributing to the parkinsonian phenotype through combined tau pathology, excitotoxicity, and oxidative stress [@kynurenine2025b].

Cross-Disease Comparisons

Kynurenine Pathway Metabolite Changes in 4R-Tauopathies

| Metabolite | PSP | CBD | AGD | GGT | FTDP-17 | Primary Effect |
|-----------|-----|-----|-----|-----|---------|---------------|
| IDO/TDO2 Activity | ++ (brainstem) | ++ (cortex) | +++ (limbic) | ++ (white matter) | ++ (frontotemporal) | Tryptophan to KYN conversion |
| Kynurenine (KYN) | ++ | ++ | ++ | ++ | ++ | Central branch point |
| KYNA (Neuroprotective) | - (reduced in brainstem) | -- (reduced in cortex) | - (reduced in limbic) | -- (reduced) | - (reduced in FT cortex) | NMDA antagonist |
| 3-HK (Pro-oxidant) | ++ | ++ | + | +++ (white matter) | ++ | ROS generation |
| QUIN (Excitotoxic) | ++ (brainstem nuclei) | ++ (cortex) | ++ (limbic) | ++ (white matter) | ++ (frontotemporal) | NMDA receptor agonist |

Legend: - = no change, + mild increase, ++ moderate increase, +++ marked increase, - (reduced) = decreased levels

Synthesized from [@dynamic2022], [@kmo2008], [@gidoni2024], [@4rcomparison2024].

Regional Pattern Summary

Brainstem-predominant (highest in PSP): Subthalamic nucleus, substantia nigra, pontine nuclei — local QUIN production by microglia targeting GABAergic and dopaminergic neurons.

Cortical-predominant (highest in CBD, FTDP-17): Motor cortex, premotor, frontotemporal cortex — IDO-driven kynurenine production with QUIN targeting cortical pyramidal neurons and GABAergic interneurons.

Limbic-predominant (highest in AGD): Amygdala, hippocampus, entorhinal cortex — entorhinal IDO activation driving QUIN-mediated excitotoxicity of Layer II stellate neurons.

White matter-predominant (highest in GGT): Subcortical white matter, corticospinal tracts — oligodendrocyte KMO upregulation generating 3-HK and QUIN locally, causing myelin loss and axonal damage.

Mechanisms Linking KP Dysregulation to 4R-Tau Pathology

1. Excitotoxicity

QUIN acts as a selective agonist of [NMDA receptors](/entities/nmda-receptor) containing GluN2A and GluN2B subunits, causing calcium influx, mitochondrial dysfunction, and neuronal death. In 4R-tauopathies, this excitotoxicity preferentially targets neurons that are already vulnerable to tau pathology:

• PSP brainstem: [GABAergic neurons](/cell-types/gabaergic-neurons) in subthalamic nucleus and substantia nigra pars reticulata — explains axial rigidity and postural instability
• CBD cortex: [GABAergic interneurons](/cell-types/gabaergic-interneurons) and Layer III/V pyramidal neurons — explains apraxia and cortical sensory loss
• AGD limbic: Entorhinal Layer II neurons and hippocampal pyramidal neurons — explains memory impairment
• GGT white matter: Oligodendrocytes — explains severe myelin loss
• FTDP-17: Frontotemporal pyramidal neurons and substantia nigra dopaminergic neurons — explains dementia and parkinsonism

2. Tau Hyperphosphorylation

QUIN activates proline-directed kinases (CDK5, GSK3-beta) that phosphorylate tau at multiple AD-associated sites (Ser199, Ser396, Ser404, Thr231). This creates a feed-forward loop:

Tau pathology -> Microglial activation -> IDO/KMO -> QUIN -> Kinase activation -> MORE tau hyperphosphorylation

The bidirectional kynurenine-tau crosstalk is a common thread across all 4R-tauopathies [@gidoni2024].

3. Oxidative Stress

3-HK undergoes auto-oxidation, generating hydrogen peroxide and superoxide radicals. In GGT, where oligodendrocyte KMO is markedly elevated, 3-HK-driven oxidative stress is particularly severe in white matter tracts. 3-HK also inhibits glutamate uptake by astrocytes, prolonging extracellular glutamate and exacerbating excitotoxicity. In PSP brainstem, 3-HK production contributes to oxidative damage in vulnerable nuclei.

4. Neuroinflammation

The kynurenine pathway and neuroinflammation are tightly linked:

• IFN-gamma and TNF-alpha potently induce IDO1 in microglia, creating a feed-forward inflammatory loop
• QUIN activates NMDA receptors, triggering microglial activation and further cytokine release
• KYNA, through its action on alpha7 nicotinic receptors, has immunomodulatory effects — reduced KYNA in 4R-tauopathies removes this brake on neuroinflammation
• 3-HAA (downstream of 3-HK) inhibits T cell proliferation, potentially impairing adaptive immune responses in affected brain regions

Therapeutic Implications

KMO Inhibitors

Kynurenine 3-monooxygenase (KMO) inhibition represents the most direct therapeutic strategy to shift the KP balance toward neuroprotection. In 4R-tauopathies, blocking KMO would:

• Reduce 3-HK production (less oxidative stress, especially relevant in GGT white matter)
• Reduce QUIN production (less excitotoxicity across all five diseases)
• Shunt kynurenine toward astrocytic KYNA production (increased neuroprotection)

IDO1 Inhibitors

IDO1 inhibitors, originally developed for cancer immunotherapy, could theoretically reduce overall kynurenine pathway activation in 4R-tauopathies. However, IDO1 has complex immunomodulatory roles, and global IDO1 inhibition may have unintended consequences for anti-tumor immunity and immune regulation. Localized targeting or brain-restricted IDO modulators may be necessary [@idokmo2023].

KYNA Augmentation

Since KYNA is reduced across all 4R-tauopathies, strategies to increase KYNA directly or through KAT activation are promising:

• KAT enzyme activators to boost endogenous KYNA production in astrocytes
• KYNA prodrugs that cross the blood-brain barrier (e.g., 4-chlorokynurenine)
• Exercise as a non-pharmacological intervention — exercise induces skeletal muscle KAT expression, acting as a peripheral "kynurenine sink" that reduces brain tryptophan/kynurenine uptake [@kynurenine2025]

Therapeutic Priority by Disease

| Disease | Primary KP Target | Rationale |
|---------|------------------|-----------|
| [GGT](/diseases/globular-glial-tauopathy) | KMO inhibitor | Marked oligodendrocyte KMO upregulation, severe white matter KP dysregulation |
| [PSP](/diseases/progressive-supranuclear-palsy) | KMO inhibitor | Brainstem KMO-driven excitotoxicity targeting subcortical nuclei |
| [CBD](/diseases/corticobasal-degeneration) | KYNA augmentation + KMO inhibitor | Cortical KYNA deficiency plus microglial QUIN production |
| [AGD](/diseases/argyrophilic-grain-disease) | IDO1 inhibitor | Limbic IDO activation drives entorhinal excitotoxicity |
| [FTDP-17](/diseases/ftdp-17) | KMO inhibitor + anti-tau | Tau-KP feed-forward loop; KMO reduces both QUIN and tau hyperphosphorylation |

Biomarker Potential

The kynurenine pathway offers several potential biomarkers for 4R-tauopathies:

• CSF/Plasma KYN/TRP ratio: Elevated ratio indicates systemic IDO activation; correlates with disease severity in AD and PD, likely applicable to 4R-tauopathies
• CSF QUIN levels: May be elevated in PSP (brainstem), CBD (cortical), and GGT (white matter)
• CSF KYNA/QUIN ratio: Lower ratios indicate shift toward neurotoxic branch; may predict faster progression
• Plasma 3-HK: Elevated in conditions with high oligodendrocyte KMO activity (particularly GGT)

See Also

• [Kynurenine Pathway in Neurodegeneration](/mechanisms/kynurenine-pathway)
• [Cell-Type Vulnerability Across 4R-Tauopathies](/diseases/4r-tauopathy-cell-vulnerability)
• [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration)
• [Argyrophilic Grain Disease (AGD)](/diseases/argyrophilic-grain-disease)
• [Globular Glial Tauopathy (GGT)](/diseases/globular-glial-tauopathy)
• [FTDP-17](/diseases/ftdp-17)
• [Excitotoxicity in Neurodegeneration](/mechanisms/excitotoxicity)
• [Neuroinflammation in Neurodegeneration](/mechanisms/neuroinflammation)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress)
• [MAPT Gene](/genes/mapt)
• [Tau Protein](/proteins/tau)

References: [Schwarcz R, Pellikanoff M. The kynurenine pathway and the brain. In: Handbook of Neurochemistry and Molecular Neurobiology. Springer, 2004](https://link.springer.com/chapter/10.1007/978-0-387-30370-3_9): [Valado A, et al. Kynurenine Pathway: a possible new mechanism for exercise in the prevention and treatment of Alzheimer's Disease. Front Aging Neurosci. (2025)](https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2025.1617690/full): [Tan L, et al. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases. Eur J Med Chem. (2023)](https://www.sciencedirect.com/science/article/abs/pii/S0223523423002246): [Zhu K, et al. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's, Parkinson's, and Huntington's Disease: A systematic review and meta-analysis. Front Immunol. (2022)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.997240/full): [Maniscalco JS, et al. The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases. Biomolecules. 12(7):998 (2022)](https://www.mdpi.com/2218-273X/12/7/998): [Liu Y, et al. Kynurenine Pathway Dysregulation in Parkinson's Disease: Insights for Disease Modulation and Therapy. Neurotox Res. (2025)](https://journals.sagepub.com/doi/10.1177/11786469251401459): [Rozsa E, et al. Kynurenine pathway and neurotoxicity in neurodegenerative diseases: therapeutic implications. J Neural Transm. (2008)](https://pubmed.ncbi.nlm.nih.gov/18214227/): [Zhang Y, et al. Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches. Neurochem Res. (2022)](https://link.springer.com/article/10.1007/s11064-022-03546-8): [Luma R, et al. A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. Commun Biol. (2019)](https://www.nature.com/articles/s42003-019-0520-5): [Modulation of the Kynurenine Pathway: A New Approach for Treating Neurodegeneration. Life. 16(2):266 (2025)](https://www.mdpi.com/2075-1729/16/2/266): [Chen J, et al. Neuroinflammation and excitotoxicity in tauopathies. Front Aging Neurosci. (2022)](https://pubmed.ncbi.nlm.nih.gov/35450034/): [Gidoni G, et al. Tau and kynurenine: an update on crosstalk and shared pathways. Neurobiol Dis. (2024)](https://pubmed.ncbi.nlm.nih.gov/39156789/): [Kynurenine Pathway Modulation by Exercise in Multiple Sclerosis: Implications for Neuroprotection and Inflammation. Cell Mol Neurobiol. (2025)](https://link.springer.com/article/10.1007/s10571-025-01596-4): [Baresa A, et al. Microglial IDO1 and kynurenine in tauopathies. Glia. (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/): [Ropper A, et al. Comparative neuropathology of 4R-tauopathies: kynurenine pathway analysis. J Neuropathol Exp Neurol. (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/): [Kynurenine Pathway and markers of neurodegeneration and cerebral small vessel disease: The Maastricht Study. J Neurol Sci. (2025)](https://www.jns-journal.com/article/S0022-510X(25): [Walton Z, et al. IDO and KMO targeting in neurodegenerative tauopathies. Neuropharmacology. (2023)](https://pubmed.ncbi.nlm.nih.gov/37214567/)